A historic day in Crude yesterday with unprecedented volatility. The May contract made highs of 113.41, +25.89 [+30%] before falling to lows of 79.00 [-9.73%]. This comes out to a whopping trading ...
RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.
When biometric identifiers are compromised, they cannot be replaced like a password, and the consequences can be irreversible ...
The original news release incorrectly listed the executive contact as Sean Samson, President and CEO. The correct contact information should read: John PatersonInterim President and CEOEV Nickel ...
Decree 03/2026 stipulates that by March 31st of each year at the latest, social funds and charitable funds must publicly ...
How can we harness our anxiety in everything from parenting to investing?
G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...
Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.
Quest Resource Holding Corporation stated that, "pipeline remains very healthy," but conversion timelines are delayed due to macroeconomic uncertainty. CEO Perry W. Moss emphasized that operational ...
One of the conversation topics late last week in Deer Valley is the weather and climate, and more specifically that Salt Lake ...
Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results